SCHEMBL7770511

SCHEMBL7770511

O=P(O)(O)Cc1cccc(O)c1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.53
IAPP P10997 4/20 0.47
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
PGK1 P00558 2/20 0.45
PGK2 P07205 2/20 0.45
ADAMTS4 O75173 1/20 0.44
ALDH1A1 P00352 1/20 0.44
EGFR P00533 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
LMNA P02545 1/20 0.44
FYN P06241 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1585388 0.98 ACP3 (0.52) ACP3IAPPGRIN2DGRIN3BGRIN1
Phosphoric Acid SCHEMBL466514 0.83 GABRA1 (0.64) IAPPADAMTS4ALDH1A1EGFRCA1
SCHEMBL915357 0.83 ACP3 (0.57) ACP3GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL14769204 0.80 IAPP (0.53) IAPPADAMTS4ALDH1A1EGFRCA1
SCHEMBL915456 0.80 ACP3 (0.65) ACP3GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1585391 0.80 IAPP (0.44) IAPPADAMTS4ALDH1A1EGFRCA1
SCHEMBL27609859 0.80 ACP3 (0.50) ACP3GRIN2DGRIN3BGRIN1GRIN2A
Pyrogallol SCHEMBL27844566 0.79 ALDH1A1 (0.71) IAPPADAMTS4ALDH1A1EGFRCA1
Pyrogallol SCHEMBL5606364 0.79 ALDH1A1 (0.71) IAPPADAMTS4ALDH1A1EGFRCA1
SCHEMBL1585364 0.79 IAPP (0.51) IAPPADAMTS4ALDH1A1EGFRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0690064-B1 Process for preparing sterically hindered hydroxybenzylphosphonates CIBA SC HOLDING AG (CH) 2001-07-11 EP claimed
US-20130065857-A1 NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY BAYLOR COLLEGE OF MEDICINE (US) 2013-03-14 US disclosed
US-20130065857-A1 NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY BAYLOR COLLEGE OF MEDICINE (US) 2013-03-14 US disclosed
EP-0690064-B1 Process for preparing sterically hindered hydroxybenzylphosphonates CIBA SC HOLDING AG (CH) 2001-07-11 EP disclosed
EP-0507738-B1 Process for preparing sterically mindered hydroxybenzylphosphonates CIBA GEIGY AG (CH) 1996-07-17 EP disclosed
EP-0690064-A1 Process for preparing sterically hindered hydroxybenzylphosphonates CIBA-GEIGY AG (CH) 1996-01-03 EP disclosed
EP-0507738-A2 Process for preparing sterically mindered hydroxybenzylphosphonates CIBA-GEIGY AG (CH) 1992-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065857-A1 NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY DDX18, FPR1, DCXR ACP3 4134/4885IAPP 4764/4885GRIN2D 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.